Ani Pharmaceuticals Inc., of Baudette, Minn., priced an underwritten public offering of 1.5 million shares of its common stock at $50 each. Gross proceeds are expected to be $75 million. The company granted the underwriters a 30-day option to purchase up to an additional 225,000 shares. Guggenheim Securities is acting as lead book-running manager for the offering. Raymond James is also acting as book-running manager. H.C. Wainwright & Co. is serving as lead manager. Shares of Ani (NASDAQ:ANIP) closed Nov. 4 at $50, down $6.66.

Cellenkos Inc., of Houston, closed its $15 million series A financing led by BVCF Management Ltd. Proceeds will be used to further its development on the regulatory T-cell therapy platform to address unmet needs in autoimmune and inflammatory disorders, the company said.

Concert Pharmaceuticals Inc., of Lexington, Mass., signed an agreement with BVF Partners LP and RA Capital Management to raise gross proceeds of $65 million. Concert also will have the potential to receive another $103 million upon the full exercise of warrants being issued in connection with the agreement. Closing of the financing is expected on or about Nov. 5, 2021.

Evotec SE, of Hamburg, Germany, decided on the volume and the issue price of its public offering of American depositary shares (ADSs). The offering will produce gross proceeds of $435 million from the sale of 10 million ordinary shares of Evotec in the form of 20 million ADSs at a price of $21.75 per ADS. Each ADS will represent one-half of an ordinary share of Evotec. The company’s ADSs’ (NASDAQ:EVO) closed Nov. 4 at $22, up 25 cents.

Mission Biocapital, of Cambridge, Mass., a venture capital firm focused on making investments in early stage life sciences companies, said it has raised $275 million for its next round of investments. Mission Biocapital V LP is more than double the size of the firm’s prior fund, the company noted. Funding will continue for companies working with therapeutics, as well as investments in diagnostics, medical devices, laboratory tools and drug delivery.

Oramed Pharmaceuticals Inc., of New York, signed definitive agreements with several institutional and accredited investors for the sale and issuance, in a registered direct offering priced at-the-market under Nasdaq rules, of 2 million shares of common stock at $25 each for $50 million. H.C. Wainwright & Co. is acting as the exclusive placement agent for the offering.

Orphazyme A/S, of Copenhagen, filed to issue and sell American depositary shares (ADSs) with an aggregate offering price of up to $50 million, with each ADS representing one ordinary share of the company, to be sold in the U.S. at market price, from time to time, at its option, in “at the market” transactions. The sales are pursuant to an agreement with Cowen and Co. LLC.

Parthenon Therapeutics Inc., of Cambridge, Mass., disclosed a $65 million series A financing led by Northpond Ventures, Pfizer Ventures and Taiho Ventures. Additional investors included Section 32, Breakout Ventures, funds managed by Tekla Capital Management LLC, Creacion Ventures, KdT Ventures, Park West Asset Management LLC and Alexandria Venture Investments. The company plans to use the funds to develop new therapies that target immune exclusion in tumors.

Plateletbio Inc., of Watertown, Mass., raised $75.5 million in a series B financing. The round includes new investors Symbiosis, K2 Healthventures and Oxford Finance as well as participation from existing investors Ziff Capital Partners and Qiming Venture Partners. The company will use the proceeds to continue preclinical development of its lead platelet-like cell program as a therapy for immune thrombocytopenia, among other projects. The company has expanded its board with the addition of Chidozie Ugwumba, managing partner of Symbiosis.